Skip to main content
2023 Midyear Clinical Meeting & Exhibition Main banner
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Presentation Icons
Certfified Pharmacy Executive Leader (CPEL)
Certfified Pharmacy Executive Leader (CPEL)
Integrated Informatics Institute
Integrated Informatics Institute
Handout

Clinical Sessions for Recertification

Educational Sessions

Board Certification Activities

Amyloidosis: Updates and Clinical Management

Tuesday, December 5, 2023
2:00 PM - 4:00 PM  
Location: ACC North, Room 256, 200 Level
CE Credits 2.00 contact hours
Planned in cooperation with the American College of Clinical Pharmacy
Activity #: 0217-9999-23-076-L01-P
Activity Type: Application-based
Target Audience: Pharmacist, Board-Certified Pharmacist
NOTE: This session is part of the Live Intensive Studies and Clinical Sessions packages. All attendees may attend these thought-provoking and highly educational sessions. However, if you are board certified, you must purchase the package(s) for your specialty to receive the recertification assessment and claim the recertification credit.

This session will evaluate recent literature and updates in the area of amyloidosis, focusing on the last 5 years and the impact on clinical management based on these updates. The speakers will cover the following subtopics: updates in AL amyloidosis management, new therapeutics in the pipeline and/or being used off-label in this area, updates in ATTR therapeutics, including vutirisan place in therapy, supportive care updates, and incorporating new guideline recommendations in practice. There will be discussion of case-based examples of these subtopics and how to incorporate these recommendations in clinical practice, and participants will identify strategies that institutions have identified on managing formulary incorporation of newer therapies, and strategies incorporated for cost, access, and adherence to novel therapies.

This activity is approved for Board Certified Oncology Pharmacist (BCOP) recertification credit.

Learning Objectives:

  • Develop appropriate counseling points on therapy recommendations for amyloidosis.
  • Identify initiation of therapy for light-chain (AL) amyloidosis patients as either first-line or relapsed/refractory disease.
  • Compose a treatment plan for a patient with transthyretin-related (ATTR) amyloidosis based on recommendations from current guideline recommendations.
  • Interpret the financial impact of therapy of disease-modifying agents and supportive care therapies in amyloidosis.
  • Prepare best supportive care recommendations and monitoring for patients with amyloidosis.